Aminoglycosides--engineering important patient-centered outcomes with antibiotics.
David W
DW
Noble
D058186:Acute Kidney Injury / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology*; D000617:Aminoglycosides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D003404:Creatinine / Q000097:blood; D055316:Cystatin C / Q000097:blood; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007362:Intensive Care Units; D007677:Kidney Function Tests; D013552:Swine; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D014031:Tobramycin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D016896:Treatment Outcome; D014882:Water-Electrolyte Balance / Q000187:drug effects / Q000502:physiology
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D055316:Cystatin C; D003404:Creatinine; D014031:Tobramycin